Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 31 | 2024 | 850 | 3.360 |
Why?
|
| Schools, Medical | 5 | 2018 | 135 | 2.390 |
Why?
|
| Students, Medical | 10 | 2022 | 423 | 2.290 |
Why?
|
| China | 19 | 2022 | 235 | 1.940 |
Why?
|
| Education, Medical | 6 | 2019 | 242 | 1.620 |
Why?
|
| Education, Medical, Undergraduate | 3 | 2019 | 180 | 1.510 |
Why?
|
| Curriculum | 8 | 2019 | 572 | 1.260 |
Why?
|
| Anti-HIV Agents | 7 | 2013 | 160 | 1.020 |
Why?
|
| Attitude of Health Personnel | 4 | 2019 | 654 | 0.990 |
Why?
|
| Immunocompromised Host | 2 | 2023 | 142 | 0.900 |
Why?
|
| Women's Health | 2 | 2019 | 103 | 0.780 |
Why?
|
| Teaching | 3 | 2017 | 146 | 0.740 |
Why?
|
| Internship and Residency | 4 | 2019 | 1063 | 0.730 |
Why?
|
| Anti-Retroviral Agents | 5 | 2023 | 32 | 0.730 |
Why?
|
| Educational Measurement | 4 | 2019 | 231 | 0.720 |
Why?
|
| Transplant Recipients | 1 | 2021 | 142 | 0.670 |
Why?
|
| International Cooperation | 2 | 2013 | 127 | 0.650 |
Why?
|
| HIV-1 | 5 | 2007 | 165 | 0.620 |
Why?
|
| Cardiovascular Diseases | 3 | 2014 | 716 | 0.620 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2003 | 73 | 0.600 |
Why?
|
| Ethics, Medical | 2 | 2017 | 306 | 0.580 |
Why?
|
| Reference Standards | 1 | 2018 | 143 | 0.570 |
Why?
|
| Neurosciences | 2 | 2016 | 52 | 0.570 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2017 | 9 | 0.570 |
Why?
|
| Geriatrics | 1 | 2018 | 66 | 0.570 |
Why?
|
| Neurologists | 1 | 2016 | 7 | 0.550 |
Why?
|
| Neurosurgeons | 1 | 2016 | 37 | 0.540 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2019 | 81 | 0.520 |
Why?
|
| Health Care Reform | 1 | 2017 | 85 | 0.520 |
Why?
|
| Surveys and Questionnaires | 9 | 2024 | 2658 | 0.510 |
Why?
|
| Humans | 55 | 2024 | 90014 | 0.510 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2023 | 148 | 0.510 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2005 | 23 | 0.490 |
Why?
|
| Career Choice | 1 | 2016 | 148 | 0.490 |
Why?
|
| Histology | 1 | 2014 | 4 | 0.490 |
Why?
|
| Physiology | 1 | 2014 | 17 | 0.480 |
Why?
|
| Health Communication | 1 | 2014 | 13 | 0.470 |
Why?
|
| Mental Health Services | 2 | 2014 | 59 | 0.460 |
Why?
|
| Health Services Accessibility | 3 | 2011 | 438 | 0.460 |
Why?
|
| Internal Medicine | 1 | 2018 | 362 | 0.450 |
Why?
|
| Cross Infection | 1 | 2015 | 151 | 0.430 |
Why?
|
| Communication | 2 | 2014 | 462 | 0.430 |
Why?
|
| Suicidal Ideation | 1 | 2014 | 74 | 0.430 |
Why?
|
| Competency-Based Education | 3 | 2019 | 38 | 0.420 |
Why?
|
| Drugs, Generic | 1 | 2013 | 21 | 0.420 |
Why?
|
| Clostridium Infections | 1 | 2015 | 125 | 0.410 |
Why?
|
| Depression | 2 | 2014 | 513 | 0.410 |
Why?
|
| Cross-Sectional Studies | 7 | 2019 | 1729 | 0.410 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 72 | 0.410 |
Why?
|
| Delivery of Health Care | 3 | 2011 | 437 | 0.390 |
Why?
|
| Health Care Surveys | 3 | 2017 | 281 | 0.380 |
Why?
|
| HIV Protease Inhibitors | 4 | 2007 | 21 | 0.380 |
Why?
|
| Faculty, Medical | 3 | 2019 | 188 | 0.370 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 365 | 0.370 |
Why?
|
| Male | 25 | 2024 | 42705 | 0.370 |
Why?
|
| Adult | 20 | 2024 | 26845 | 0.350 |
Why?
|
| Female | 25 | 2024 | 46620 | 0.340 |
Why?
|
| Physician-Patient Relations | 2 | 2014 | 625 | 0.330 |
Why?
|
| Sexual and Gender Minorities | 2 | 2023 | 215 | 0.330 |
Why?
|
| Telemedicine | 2 | 2022 | 195 | 0.320 |
Why?
|
| Antiviral Agents | 3 | 2023 | 482 | 0.300 |
Why?
|
| Preventive Health Services | 1 | 2008 | 39 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2018 | 540 | 0.300 |
Why?
|
| Clinical Competence | 4 | 2018 | 796 | 0.290 |
Why?
|
| Young Adult | 8 | 2021 | 6423 | 0.280 |
Why?
|
| Mentors | 2 | 2018 | 90 | 0.270 |
Why?
|
| Qualitative Research | 3 | 2024 | 306 | 0.260 |
Why?
|
| Patient Compliance | 4 | 2003 | 230 | 0.260 |
Why?
|
| Neoplasms | 1 | 2021 | 3065 | 0.260 |
Why?
|
| Hospitalization | 2 | 2021 | 888 | 0.250 |
Why?
|
| Health Education | 2 | 2012 | 105 | 0.250 |
Why?
|
| Sulfonamides | 1 | 2007 | 320 | 0.230 |
Why?
|
| Drug Therapy, Combination | 6 | 2007 | 785 | 0.230 |
Why?
|
| Developing Countries | 1 | 2004 | 80 | 0.230 |
Why?
|
| Global Health | 1 | 2005 | 193 | 0.220 |
Why?
|
| Cell Phone | 1 | 2023 | 38 | 0.220 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 92 | 0.210 |
Why?
|
| Adolescent | 8 | 2021 | 9352 | 0.210 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 403 | 0.210 |
Why?
|
| Poverty | 1 | 2004 | 183 | 0.210 |
Why?
|
| Indinavir | 1 | 2002 | 3 | 0.210 |
Why?
|
| Program Evaluation | 3 | 2024 | 311 | 0.210 |
Why?
|
| Crowdsourcing | 1 | 2022 | 12 | 0.210 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 65 | 0.200 |
Why?
|
| Continuity of Patient Care | 1 | 2024 | 172 | 0.200 |
Why?
|
| Mobile Applications | 1 | 2023 | 71 | 0.200 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 462 | 0.200 |
Why?
|
| Middle Aged | 12 | 2024 | 26179 | 0.200 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 469 | 0.180 |
Why?
|
| Social Support | 1 | 2002 | 216 | 0.180 |
Why?
|
| Cryptococcus neoformans | 1 | 2019 | 9 | 0.170 |
Why?
|
| Cryptococcosis | 1 | 2019 | 11 | 0.170 |
Why?
|
| Opportunistic Infections | 1 | 2019 | 60 | 0.170 |
Why?
|
| Viral Load | 5 | 2007 | 145 | 0.170 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2000 | 59 | 0.160 |
Why?
|
| Licensure, Medical | 1 | 2019 | 20 | 0.160 |
Why?
|
| Reproductive Health | 1 | 2019 | 34 | 0.160 |
Why?
|
| Retrospective Studies | 6 | 2022 | 9239 | 0.160 |
Why?
|
| Primary Health Care | 1 | 2002 | 352 | 0.160 |
Why?
|
| Prevalence | 3 | 2015 | 1250 | 0.160 |
Why?
|
| HIV Wasting Syndrome | 1 | 1998 | 2 | 0.150 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 358 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2021 | 326 | 0.150 |
Why?
|
| Chicago | 5 | 2002 | 1434 | 0.150 |
Why?
|
| Gynecology | 1 | 2019 | 129 | 0.150 |
Why?
|
| Problem-Based Learning | 1 | 2017 | 35 | 0.140 |
Why?
|
| Capacity Building | 1 | 2017 | 12 | 0.140 |
Why?
|
| Hospice Care | 1 | 2017 | 40 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6784 | 0.140 |
Why?
|
| Universities | 1 | 2018 | 146 | 0.140 |
Why?
|
| Zidovudine | 1 | 1996 | 16 | 0.140 |
Why?
|
| Comprehensive Health Care | 1 | 1996 | 13 | 0.140 |
Why?
|
| Models, Organizational | 1 | 1996 | 48 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 127 | 0.130 |
Why?
|
| Medication Adherence | 2 | 2022 | 139 | 0.130 |
Why?
|
| Risk Factors | 4 | 2014 | 5566 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 1996 | 59 | 0.130 |
Why?
|
| Education, Public Health Professional | 1 | 2015 | 2 | 0.130 |
Why?
|
| Data Collection | 2 | 2014 | 377 | 0.130 |
Why?
|
| United States | 4 | 2019 | 7115 | 0.130 |
Why?
|
| Palliative Care | 1 | 2017 | 264 | 0.130 |
Why?
|
| Learning | 1 | 2018 | 285 | 0.120 |
Why?
|
| Aged | 4 | 2021 | 19269 | 0.120 |
Why?
|
| Quality of Health Care | 1 | 2018 | 387 | 0.120 |
Why?
|
| HIV Seroprevalence | 1 | 1994 | 9 | 0.120 |
Why?
|
| Self-Assessment | 1 | 2014 | 47 | 0.110 |
Why?
|
| Professional-Patient Relations | 1 | 2014 | 54 | 0.110 |
Why?
|
| Specialization | 1 | 2014 | 70 | 0.110 |
Why?
|
| Syphilis | 1 | 1994 | 33 | 0.110 |
Why?
|
| Health Surveys | 1 | 2014 | 240 | 0.110 |
Why?
|
| Neurology | 1 | 2014 | 75 | 0.110 |
Why?
|
| Focus Groups | 1 | 2014 | 177 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2017 | 405 | 0.100 |
Why?
|
| Patient Medication Knowledge | 1 | 2012 | 1 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1994 | 99 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2016 | 457 | 0.100 |
Why?
|
| Attitude | 1 | 2013 | 130 | 0.100 |
Why?
|
| Psychiatry | 1 | 2013 | 82 | 0.100 |
Why?
|
| Directive Counseling | 1 | 2012 | 35 | 0.100 |
Why?
|
| Physician's Role | 2 | 1996 | 176 | 0.090 |
Why?
|
| Social Stigma | 1 | 2012 | 70 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2012 | 93 | 0.090 |
Why?
|
| HIV Seropositivity | 2 | 1988 | 51 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2014 | 776 | 0.090 |
Why?
|
| Smoking | 1 | 2014 | 625 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2023 | 872 | 0.090 |
Why?
|
| Child | 4 | 2004 | 7241 | 0.090 |
Why?
|
| Interviews as Topic | 2 | 2024 | 344 | 0.080 |
Why?
|
| Drug Resistance, Viral | 2 | 2007 | 48 | 0.080 |
Why?
|
| Urban Population | 2 | 2002 | 224 | 0.080 |
Why?
|
| Homosexuality, Male | 2 | 2023 | 304 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1081 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 841 | 0.080 |
Why?
|
| Hypertension | 1 | 2014 | 745 | 0.080 |
Why?
|
| Role | 1 | 1988 | 11 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2019 | 8295 | 0.070 |
Why?
|
| Darunavir | 1 | 2007 | 1 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2007 | 1134 | 0.070 |
Why?
|
| Program Development | 2 | 2018 | 127 | 0.070 |
Why?
|
| Physician Assistants | 2 | 2017 | 21 | 0.070 |
Why?
|
| Nurse Practitioners | 2 | 2017 | 30 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2004 | 68 | 0.070 |
Why?
|
| Telephone | 1 | 2005 | 36 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2002 | 2886 | 0.060 |
Why?
|
| Foster Home Care | 1 | 2004 | 3 | 0.060 |
Why?
|
| Nelfinavir | 1 | 2004 | 6 | 0.060 |
Why?
|
| Ritonavir | 1 | 2004 | 12 | 0.060 |
Why?
|
| Pyrimidinones | 1 | 2004 | 38 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2002 | 1055 | 0.050 |
Why?
|
| Case Management | 1 | 2002 | 25 | 0.050 |
Why?
|
| Transportation of Patients | 1 | 2002 | 34 | 0.050 |
Why?
|
| Republic of Korea | 2 | 2012 | 32 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2003 | 141 | 0.050 |
Why?
|
| Hospitals, Public | 1 | 2002 | 15 | 0.050 |
Why?
|
| Brazil | 2 | 2012 | 75 | 0.050 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 28 | 0.050 |
Why?
|
| Australia | 2 | 2012 | 101 | 0.050 |
Why?
|
| Health Personnel | 1 | 2024 | 214 | 0.050 |
Why?
|
| Alanine | 1 | 2021 | 84 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 784 | 0.050 |
Why?
|
| Europe | 2 | 2012 | 324 | 0.050 |
Why?
|
| Mental Health | 1 | 2002 | 180 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2004 | 1731 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 2019 | 6 | 0.040 |
Why?
|
| Fluconazole | 1 | 2019 | 11 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2019 | 34 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2002 | 284 | 0.040 |
Why?
|
| Meningitis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Social Class | 1 | 2000 | 136 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2019 | 123 | 0.040 |
Why?
|
| Physicians | 2 | 2017 | 692 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 666 | 0.040 |
Why?
|
| Formative Feedback | 1 | 2017 | 13 | 0.040 |
Why?
|
| Group Processes | 1 | 2017 | 31 | 0.040 |
Why?
|
| Cultural Competency | 1 | 2017 | 21 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 121 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 158 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 778 | 0.030 |
Why?
|
| Survival Rate | 1 | 2000 | 1898 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1994 | 23 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 1994 | 54 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 1996 | 345 | 0.030 |
Why?
|
| Mentally Ill Persons | 1 | 2013 | 6 | 0.030 |
Why?
|
| Time Factors | 1 | 2002 | 5362 | 0.030 |
Why?
|
| Cote d'Ivoire | 1 | 2012 | 2 | 0.030 |
Why?
|
| Educational Status | 1 | 2013 | 195 | 0.020 |
Why?
|
| South Africa | 1 | 2012 | 60 | 0.020 |
Why?
|
| Africa | 1 | 2012 | 101 | 0.020 |
Why?
|
| Prejudice | 1 | 2012 | 48 | 0.020 |
Why?
|
| Social Isolation | 1 | 2012 | 67 | 0.020 |
Why?
|
| Pregnancy | 2 | 1996 | 3044 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 1996 | 2494 | 0.020 |
Why?
|
| Infant | 1 | 1996 | 3189 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1075 | 0.020 |
Why?
|
| Mass Screening | 1 | 1994 | 649 | 0.020 |
Why?
|
| Child, Preschool | 1 | 1996 | 3773 | 0.020 |
Why?
|
| Coccidiosis | 1 | 1987 | 2 | 0.020 |
Why?
|
| Cryptosporidiosis | 1 | 1987 | 6 | 0.020 |
Why?
|
| Confidentiality | 1 | 1988 | 79 | 0.020 |
Why?
|
| Diarrhea | 1 | 1987 | 178 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 1987 | 120 | 0.020 |
Why?
|
| Counseling | 1 | 1988 | 166 | 0.020 |
Why?
|
| Informed Consent | 1 | 1988 | 275 | 0.020 |
Why?
|
| Stavudine | 1 | 2004 | 4 | 0.010 |
Why?
|
| Lamivudine | 1 | 2004 | 13 | 0.010 |
Why?
|
| Lopinavir | 1 | 2004 | 5 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2004 | 318 | 0.010 |
Why?
|
| Metabolic Diseases | 1 | 2003 | 51 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2003 | 163 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2004 | 328 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 846 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 865 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1714 | 0.010 |
Why?
|
| Risk Assessment | 1 | 1988 | 2327 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 960 | 0.010 |
Why?
|
| Feces | 1 | 1987 | 333 | 0.000 |
Why?
|